Shots:
- Health Canada has approved Fruzaqla to treat mCRC patients receiving prior therapy or are ineligible for SoCs based on 2 P-III (FRESCO & FRESCO-2) trials. In addition, the CDA-AMC & INESSS recommended reimbursement of Fruzaqla
- FRESCO assessed Fruzaqla + BSC vs PBO + BSC in 3L+ mCRC patients, while FRESCO-2 assessed Fruzaqla + BSC vs matching PBO in patients who progressed on or are ineligible for SoCs incl. CT, anti-VEGF/EGFR biologics, regorafenib or trifluridine-tipiracil
- Both the trials showed improved OS & mPFS. Data was published in JAMA (FRESCO) & The Lancet (FRESCO-2)
Ref: Takeda | Image: Takeda
Related News:- Takeda’s Hyqvia 10% SC Injection Receives the Japanese Approval to Treat Agammaglobulinemia or Hypogammaglobulinemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
